NCOG-19. BEVACIZUMAB IN REAL LIFE PATIENTS WITH RECURRENT GLIOBLASTOMA: BENEFIT OR FUTILITY?

Angiogenesis represents a hallmark of glioblastoma but most trials disappointed and failed to change the poor outcome of this disease. However, Bevacizumab (Bev) is widely used in clinical practice by expert oncologists due to experience or efficacy in real life.We retrospectively reviewed the use o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Smolenschi, Cristina, Colomba, Emeline, Rassy, Elie, Lezghed, Naima, Kettab, Mohamed, Louvel, Guillaume, Garcia, Gabriel, Cheaib, Bianca, Bockel, Sophie, Pallud, Johan, Dezamis, Edouard, Copaciu, Razvan, Knafo, Steven, Ammari, Samy, Dhermain, Frederic, Domont, Julien, Martanovschi, Larisa, Mahmoud, Fekih, Dumont, Sarah
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Outcome Measures and Neuro-Cognitive Outcomes
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651623/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.558
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller